Literature DB >> 11023380

Common morality versus specified principlism: reply to Richardson.

B Gert1, C M Culver, K D Clouser.   

Abstract

In his article 'Specifying, balancing and interpreting bioethical principles' (Richardson, 2000), Henry Richardson claims that the two dominant theories in bioethics--principlism, put forward by Beauchamp and Childress in Principles of Bioethics, and common morality, put forward by Gert, Culver and Clouser in Bioethics: A Return to Fundamentals--are deficient because they employ balancing rather than specification to resolve disputes between principles or rules. We show that, contrary to Richardson's claim, the major problem with principlism, either the original version or the specified principlism of Richardson, is that it conceives of morality as being composed of free-standing principles, rather than as common morality conceives it, as being a complete public system, composed of rules, ideals, morally relevant features, and a procedure for determining when a rule can be justifiably violated.

Keywords:  Analytical Approach; Bioethics and Professional Ethics; Philosophical Approach

Mesh:

Year:  2000        PMID: 11023380     DOI: 10.1076/0360-5310(200006)25:3;1-H;FT308

Source DB:  PubMed          Journal:  J Med Philos        ISSN: 0360-5310


  5 in total

1.  Organizational ethics and institutional integrity.

Authors:  A S Iltis
Journal:  HEC Forum       Date:  2001-12

Review 2.  What kind of doing is clinical ethics?

Authors:  George J Agich
Journal:  Theor Med Bioeth       Date:  2005

3.  Common morality and moral reform.

Authors:  K A Wallace
Journal:  Theor Med Bioeth       Date:  2009

4.  Research and Global Health Emergencies: On the Essential Role of Best Practice.

Authors:  Nayha Sethi
Journal:  Public Health Ethics       Date:  2018-07-24       Impact factor: 1.940

5.  Knowledge of Partial Awareness in Disorders of Consciousness: Implications for Ethical Evaluations?

Authors:  Orsolya Friedrich
Journal:  Neuroethics       Date:  2011-12-09       Impact factor: 1.480

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.